Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 12/2004

01-12-2004 | Meeting Report

Cancer Immunotherapy 2004: Mainz, Germany, 6–7 May 2004

Authors: C. M. Britten, L. Mueller, A. Knights, G. Pawelec

Published in: Cancer Immunology, Immunotherapy | Issue 12/2004

Login to get access

Excerpt

Cancer Immunotherapy 2004 was the second international meeting organized by the Association for Immunotherapy of Cancer, which represents an interdisciplinary group of 50 predominantly German clinicians and scientists working in the field of tumor immunology and immunotherapy. The scientific program was divided into four consecutive workshops—on antibody therapy, immune escape mechanisms and NK cells, adoptive T-cell transfer, and therapeutic vaccination—to focus on the most important aspects of cancer therapy. In this meeting report, we highlight selected topics presented during two lively and fascinating days on cancer immunotherapy. …
Metadata
Title
Cancer Immunotherapy 2004: Mainz, Germany, 6–7 May 2004
Authors
C. M. Britten
L. Mueller
A. Knights
G. Pawelec
Publication date
01-12-2004
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 12/2004
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-004-0580-2

Other articles of this Issue 12/2004

Cancer Immunology, Immunotherapy 12/2004 Go to the issue

Original Article

Evidence for immune defects in breast and lung cancer patients

Original Article

Monocyte-derived dendritic cells that capture dead tumor cells secrete IL-12 and TNF-α through IL-12/TNF-α/NF-κB autocrine loop

Review

Targeting the immune system: novel therapeutic approaches in squamous cell carcinoma of the head and neck

Original Article

Dendritic cell–tumor cell hybrid vaccination for metastatic cancer

Original Article

Analysis of the autoantibody repertoire in Burkitt’s lymphoma patients: frequent response against the transcription factor ATF-2

Original Article

CD4+ T cells kill Id+ B-lymphoma cells: FasLigand-Fas interaction is dominant in vitro but is redundant in vivo
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits